LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OVID
Ovid Therapeutics Inc.
There isn't enough reported data to score OVID yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OVID Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OVID's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OVID PE Valuation
OVID has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OVID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OVID's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OVID on earnings quality, reporting a profit while its opponent remains loss making.
OVID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | +$0.33 |
| Q2 2026 | -$0.23 | +$0.29 |
| Q1 2026 | -$0.21 | +$0.13 |
| Q4 2025 | -$0.23 | +$0.14 |
| Q3 2025 | -$0.49 | -$0.03 |
| Q2 2025 | -$0.52 | -$0.10 |
| Q1 2025 | -$0.34 | +$0.38 |
| Q4 2024 | -$0.37 | +$0.37 |
OVID is still losing money, but far less than before: $0.16 per share over the past year, against $1.46 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OVID on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OVID on profitability, with a higher operating margin.
OVID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $733K | -88% |
| Q4 2025 | $718K | +845% |
| Q3 2025 | $132K | -24% |
| Q2 2025 | $6.3M | +3611% |
| Q1 2025 | $130K | -12% |
| Q4 2024 | $76K | -46% |
| Q3 2024 | $173K | +59% |
| Q2 2024 | $169K | +125% |
OVID's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2142% | -2061 points |
| Q4 2025 | -1712% | +12396 points |
| Q3 2025 | -9487% | -1842 points |
| Q2 2025 | -81% | +12059 points |
| Q1 2025 | -9654% | +2114 points |
| Q4 2024 | -14108% | -1260 points |
| Q3 2024 | -7645% | +3393 points |
| Q2 2024 | -12140% | +6756 points |
OVID's operating margin was −2142% last quarter, up 7512 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OVID on cash generation, producing positive trailing cash flow while its opponent burns cash.
OVID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$3M |
| Q2 2026 | -$17.6M | -$12.8M |
| Q1 2026 | -$13.9M | -$3.6M |
| Q4 2025 | -$10.4M | -$378K |
| Q3 2025 | -$12.9M | +$2.1M |
| Q2 2025 | -$4.8M | +$9.5M |
| Q1 2025 | -$10.3M | +$6.4M |
| Q4 2024 | -$10M | +$1.9M |
OVID has burned cash in almost every quarter: −$58M over the past year, against −$38M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OVID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OVID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -6.6M shares |
| 1 year | +165% | +118M shares |
| 3 years | +167% | +118M shares |
| 5 years | +178% | +121M shares |
| Available history | +245% | +134M shares |
OVID has 189M diluted shares, up 165% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OVID Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.5x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.7x | Net Cash |
| Q1 2021 | -2.0x | Net Cash |
OVID has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OVID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.0 | Neutral |
| Stochastic | 62.2 | Neutral |
OVID's weekly RSI is 52 (neutral) and its Stochastic is 62 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OVID PE vs Healthcare Sector
OVID has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OVID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 4.5% above |
| 20 week MA | $2.55 | 0% above |
| 50 week MA | $2.28 | 12% above |
| 100 week MA | $1.53 | 67% above |
| 200 week MA | $2.11 | 21% above |
OVID's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
OVID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.61 | $2.61 | -43% |
| 2021 | $2.61 | $3.39 | +30% |
| 2022 | $3.39 | $1.70 | -50% |
| 2023 | $1.70 | $3.22 | +89% |
| 2024 | $3.22 | $0.97 | -70% |
| 2025 | $0.97 | $1.78 | +84% |
| 2026 YTD | $1.78 | $2.55 | +43% |
OVID has the edge over LLY on returns for 2026, with the stronger performance.